ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Medtronic: FDA warning letter issues resolved, products launching soon

March 9, 2011 12:17 pm by | 0 Comments

medtronic layoffs MDT NYSE:MDTIt’s turning out to be a good month so far for Medtronic Inc.

The company is showing Wall Street that it can play tough on health providers by going toe-to-toe with its purchasing organizations. (So much for Minnesota Nice.) And now Fridley, Minnesota-based Medtronic (NYSE: MDT) says it’s resolved U.S. Food and Drug Administration warning letter issues at two manufacturing facilities — clearing the way for new product launches.

“We are encouraged that the action plans implemented by our teams have resolved the observations identified by the FDA in both warning letters,” William A. Hawkins, Medtronic’s chairman and CEO, said in a news release.

The warning letters involved Medtronic’s Mounds View, Minnesota, location, the headquarters of the company’s Cardiac Rhythm Disease Management business, and its Juncos, Puerto Rico, plant, which is a Neuromodulation, Diabetes and Cardiac Rhythm Disease Management business location. The warning letters resulted from FDA inspections of the plants in late 2008 and 2009.

Advertisement

Analysts were reporting last year that the warning letters wereholding up launches of products including the Revo MRI-friendly pacemaker and Protecta defibrillator. The FDA approved the Revo last month, clearing the way for its product launch.

Protecta has been under an “approvable letter,” which means there are additional requirements the company needs to meet before the product is approved, said Medtronic spokesman Brian Henry. Three other Medtronic devices have also been under similar approvable letters: InterStim Therapy for Bowel Control, a nerve stimulation system meant to treat severe fecal incontinence, the Consulta/Syncra pacemaker, and the Attain Ability Plus left ventricular cardiac vein lead.

Getting the warning letter issues resolved helps clear the way for FDA approvals and resulting U.S. product launches, which Henry says are expected to be imminent.

The news sent Medtronic stock up 46 cents per share, or 1.16 percent, to $40.10 in Wednesday morning trading, even as the Dow Jones Industrial Average was slightly down.

Enhanced by Zemanta

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Chris Newmarker

Chris Newmarker is a Minnesota-based business journalist.
More posts by Author

0 comments

Stay Up To Date

Recent Comments

Research Center

Jobs Board

Next Story
UMN Medical Innovation Fellows Program Seeks Collaboration Team
Close